glp 1 grey Pfizer's win signals what's to come in obesity drug M&A How GLP-1 medications are transforming

They can influence the reward pathways associated with food, making highly palatable foods less intensely appealing

Poor response to GLP-1 therapy with continued weight loss and hyperglycaemia may occasionally indicate misdiagnosed diabetes type

Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY

Future trials should stratify patients by metabolic phenotype, incorporate mechanistic biomarkers, and include long-term follow-up to evaluate both psychiatric and metabolic endpoints

Caution is also needed in those with severe gastrointestinal disease, a history of pancreatitis, or significant psychiatric comorbidity requiring specialist input

Nausea, vomiting, diarrhea, and abdominal pain are some of the more common side effects of weight-loss medications (for a full list of side effects, visit the drug manufacturers website)